Acute Respiratory Distress Syndrome (ARDS): Pathophysiology, Clinical Features, and Evidence-Based Management

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of acute lung injury characterized by rapid onset, severe hypoxemia, and diffuse inflammatory damage to the alveolar-capillary barrier. Although commonly precipitated by sepsis, pneumonia, aspiration, major trauma, or inhalational insults, ARDS is best understood as a final common pathway of dysregulated host response leading to noncardiogenic respiratory failure.

At the core of ARDS is breakdown of alveolar epithelial integrity and capillary endothelial integrity. In the initiating phase, inflammatory mediators such as tumor necrosis factor-alpha, interleukins (notably IL-1β, IL-6, IL-8), and activated neutrophils propagate tissue injury. This inflammatory cascade increases permeability, resulting in protein-rich edema that floods alveoli. Meanwhile, surfactant dysfunction and atelectasis reduce alveolar compliance, producing ventilation-perfusion mismatch. In severe cases, diffuse alveolar damage evolves through formation of hyaline membranes that reflect injury to the alveolar lining.

Clinically, ARDS presents with rapid onset of dyspnea and worsening oxygenation within approximately one week of a known clinical insult. Physical findings may be nonspecific, often including tachypnea, hypoxemia, and diffuse crackles. The hallmark is impaired gas exchange, operationally captured by hypoxemia that is not fully explained by cardiac failure or volume overload. Diagnostic criteria incorporate timing, bilateral opacities on imaging, and respiratory failure not primarily due to left-sided heart pathology. Chest radiography classically shows bilateral infiltrates, while computed tomography may reveal dependent consolidation and heterogeneous aeration with areas of “baby lung,” reflecting limited functional pulmonary tissue.

The severity of ARDS is quantified by the PaO2/FiO2 ratio under a specified level of positive end-expiratory pressure (PEEP). More severe disease carries higher mortality and greater likelihood of mechanical ventilation complications. Importantly, ARDS is heterogeneous: inflammatory phenotypes and varying degrees of recruitability (the capacity for alveoli to reopen with appropriate pressures) influence response to therapy.

Management is fundamentally supportive while targeting the mechanisms that worsen hypoxemia. The primary evidence-based intervention is lung-protective mechanical ventilation. This strategy uses lower tidal volumes (typically 4–6 mL/kg predicted body weight) to reduce ventilator-induced lung injury, which includes barotrauma, volutrauma, atelectrauma, and biotrauma. Driving pressure and plateau pressure are monitored to minimize overdistension. PEEP is selected to maintain alveolar recruitment while balancing hemodynamic effects and the risk of overinflation.

Prone positioning is recommended for moderate to severe ARDS with persistent hypoxemia despite optimized ventilation. By redistributing ventilation and improving alveolar recruitment of dorsal regions, prone positioning enhances oxygenation and is associated with improved survival. Additional adjuncts include neuromuscular blockade in select early severe cases to facilitate synchrony with the ventilator, potentially reducing patient self-inflicted lung injury.

Fluid management is another critical component. A conservative fluid strategy may reduce pulmonary edema and improve oxygenation in many patients, provided there is careful monitoring for shock physiology and organ perfusion. Sepsis and other underlying causes must be treated promptly with antimicrobials when appropriate, source control when indicated, and hemodynamic optimization.

Pharmacologic therapies aimed at modulating inflammation have not consistently demonstrated mortality benefit in large trials. Corticosteroids are controversial; some patients may benefit in specific contexts, but routine universal use is not established. Similarly, inhaled pulmonary vasodilators may transiently improve oxygenation, often serving as a bridge to other interventions rather than a definitive therapy.

ARDS is also associated with significant long-term morbidity. Survivors frequently experience persistent functional impairment, cognitive deficits, depression, and post-intensive care syndrome (PICS). PICS spans physical weakness, anxiety or depressive symptoms, and problems with cognition and sleep. Rehabilitation, structured follow-up, and mental health screening are therefore integral to care.

Prognostication relies on both disease severity and patient-specific factors including age, comorbidities, etiology, and responsiveness to ventilatory strategies. Early recognition, evidence-based ventilatory management, prone positioning when indicated, and meticulous supportive care remain the most influential determinants of outcomes. Ongoing research focuses on biomarkers, phenotype-guided therapy, and strategies to prevent ventilator-induced lung injury.

Source: [Creator/Source] @Joostbakker19